143 related articles for article (PubMed ID: 17897483)
21. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
[TBL] [Abstract][Full Text] [Related]
22. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
23. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
24. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
[TBL] [Abstract][Full Text] [Related]
25. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
Bardin L; Kleven MS; Barret-Grévoz C; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1869-79. PubMed ID: 16237379
[TBL] [Abstract][Full Text] [Related]
26. Cloning, expression, functional coupling and pharmacological characterization of the rat dopamine D4 receptor.
Gazi L; Schoeffter P; Nunn C; Croskery K; Hoyer D; Feuerbach D
Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):555-64. PubMed ID: 10832611
[TBL] [Abstract][Full Text] [Related]
27. Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.
Heusler P; Bruins Slot L; Rauly-Lestienne I; Palmier C; Tardif S; Tourette A; Ailhaud MC; Cussac D
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jan; 379(1):87-99. PubMed ID: 18682919
[TBL] [Abstract][Full Text] [Related]
28. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
Rauly-Lestienne I; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Cussac D
Naunyn Schmiedebergs Arch Pharmacol; 2007 Oct; 376(1-2):93-105. PubMed ID: 17786406
[TBL] [Abstract][Full Text] [Related]
29. Human D2 and D4 dopamine receptors couple through betagamma G-protein subunits to inwardly rectifying K+ channels (GIRK1) in a Xenopus oocyte expression system: selective antagonism by L-741,626 and L-745,870 respectively.
Pillai G; Brown NA; McAllister G; Milligan G; Seabrook GR
Neuropharmacology; 1998 Aug; 37(8):983-7. PubMed ID: 9833627
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of antipsychotic agents at human 5-HT(1A) receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation.
Newman-Tancredi A; Verrièle L; Touzard M; Millan MJ
Eur J Pharmacol; 2001 Oct; 428(2):177-84. PubMed ID: 11675034
[TBL] [Abstract][Full Text] [Related]
31. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
Newman-Tancredi A; Assié MB; Martel JC; Cosi C; Slot LB; Palmier C; Rauly-Lestienne I; Colpaert F; Vacher B; Cussac D
Br J Pharmacol; 2007 May; 151(2):237-52. PubMed ID: 17375087
[TBL] [Abstract][Full Text] [Related]
32. Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5'-O-(gamma-thiotriphosphate) binding in rat striatal membranes.
Odagaki Y; Toyoshima R
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1304-12. PubMed ID: 16824659
[TBL] [Abstract][Full Text] [Related]
33. Effects of clozapine on the delta- and kappa-opioid receptors and the G-protein-activated K+ (GIRK) channel expressed in Xenopus oocytes.
Kobayashi T; Ikeda K; Kumanishi T
Br J Pharmacol; 1998 Feb; 123(3):421-6. PubMed ID: 9504382
[TBL] [Abstract][Full Text] [Related]
34. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
[TBL] [Abstract][Full Text] [Related]
35. Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.
Kobayashi T; Ikeda K; Kumanishi T
Br J Pharmacol; 2000 Apr; 129(8):1716-22. PubMed ID: 10780978
[TBL] [Abstract][Full Text] [Related]
36. In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles.
Assié MB; Dominguez H; Consul-Denjean N; Newman-Tancredi A
Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):441-50. PubMed ID: 16947046
[TBL] [Abstract][Full Text] [Related]
37. Effects of recent and reference antipsychotic agents at human dopamine D2 and D3 receptor signaling in Chinese hamster ovary cells.
Vanhauwe JF; Ercken M; van de Wiel D; Jurzak M; Leysen JE
Psychopharmacology (Berl); 2000 Jul; 150(4):383-90. PubMed ID: 10958079
[TBL] [Abstract][Full Text] [Related]
38. beta-Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q mu-opioid receptors.
Spivak CE; Beglan CL; Zöllner C; Surratt CK
Synapse; 2003 Jul; 49(1):55-60. PubMed ID: 12710015
[TBL] [Abstract][Full Text] [Related]
39. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
Burstein ES; Ma J; Wong S; Gao Y; Pham E; Knapp AE; Nash NR; Olsson R; Davis RE; Hacksell U; Weiner DM; Brann MR
J Pharmacol Exp Ther; 2005 Dec; 315(3):1278-87. PubMed ID: 16135699
[TBL] [Abstract][Full Text] [Related]
40. N-Desmethylclozapine, a major clozapine metabolite, acts as a selective and efficacious delta-opioid agonist at recombinant and native receptors.
Onali P; Olianas MC
Neuropsychopharmacology; 2007 Apr; 32(4):773-85. PubMed ID: 16841075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
